Assertio Announces Closing of $70 Million Convertible Senior Notes Offering
LAKE FOREST, Ill., Aug. 25, 2022 (GLOBE NEWSWIRE) –
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed its offering of $70 million aggregate principal amount of 3.00% convertible senior notes due 2027 (the “notes”),…
Assertio Holdings, Inc. is a specialty pharmaceutical company that focuses on providing unique and innovative products to patients. With the closing of its offering of $70 million convertible senior notes, the company has secured additional funds to support its growth and development initiatives.
The notes offer investors the option to purchase an additional $10 million in aggregate principal amount, providing Assertio with the potential for further capital infusion in the future. This flexibility allows the company to pursue strategic opportunities and expand its product portfolio to better serve its customers.
By leveraging the convertible senior notes, Assertio can strengthen its financial position and enhance its competitive edge in the pharmaceutical industry. The company’s commitment to innovation and patient care is evident in its continued efforts to bring new and improved products to market.
Overall, the closing of the convertible senior notes offering signifies Assertio’s dedication to sustainable growth and long-term success. With a solid financial foundation in place, the company is well-positioned to drive value for its shareholders and make a positive impact on the healthcare sector.
How Will This Affect Me?
As a consumer, the closing of Assertio’s convertible senior notes offering may not have a direct impact on you. However, it indicates that the company is taking steps to strengthen its position in the market, which could lead to the development of more innovative products for patients like you in the future.
How Will This Affect the World?
The closing of Assertio’s convertible senior notes offering demonstrates the company’s commitment to advancing healthcare and pharmaceutical innovation. By securing additional funding, Assertio can continue its research and development efforts to address unmet medical needs and improve patient outcomes on a global scale.
Conclusion
Assertio’s announcement of the closing of its $70 million convertible senior notes offering reflects the company’s strategic focus on growth and innovation in the pharmaceutical industry. With increased financial resources at its disposal, Assertio is well-positioned to drive value for its stakeholders and contribute to advancements in healthcare worldwide.
